Medidata Solutions (NASDAQ:MDSO) has been assigned a $86.00 target price by equities researchers at Royal Bank of Canada in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Royal Bank of Canada’s target price suggests a potential upside of 21.64% from the company’s current price.

MDSO has been the topic of a number of other research reports. JPMorgan Chase & Co. lowered shares of Medidata Solutions from an “overweight” rating to a “neutral” rating and set a $87.00 target price on the stock. in a report on Tuesday, July 24th. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Tuesday. ValuEngine upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a report on Friday, August 24th. Morgan Stanley set a $84.00 target price on shares of Medidata Solutions and gave the stock a “hold” rating in a report on Wednesday, July 25th. Finally, Needham & Company LLC lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Medidata Solutions presently has a consensus rating of “Buy” and an average target price of $86.33.

Shares of NASDAQ MDSO traded down $0.12 during trading on Friday, hitting $70.70. 20,218 shares of the company traded hands, compared to its average volume of 766,541. Medidata Solutions has a fifty-two week low of $59.60 and a fifty-two week high of $88.87. The firm has a market capitalization of $4.13 billion, a P/E ratio of 83.52, a P/E/G ratio of 4.35 and a beta of 1.44. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.16.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 18th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.06. Medidata Solutions had a net margin of 9.13% and a return on equity of 11.37%. The firm had revenue of $163.41 million for the quarter, compared to analyst estimates of $162.09 million. During the same quarter in the prior year, the business earned $0.33 earnings per share. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. Equities research analysts forecast that Medidata Solutions will post 0.79 EPS for the current year.

In other Medidata Solutions news, Director Lee Shapiro sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 26th. The shares were sold at an average price of $76.16, for a total value of $952,000.00. Following the completion of the sale, the director now directly owns 26,028 shares of the company’s stock, valued at approximately $1,982,292.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert Taylor sold 5,000 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $73.05, for a total transaction of $365,250.00. Following the completion of the sale, the director now directly owns 44,036 shares of the company’s stock, valued at $3,216,829.80. The disclosure for this sale can be found here. Insiders sold a total of 26,788 shares of company stock worth $2,069,857 in the last 90 days. 4.70% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. World Asset Management Inc bought a new stake in Medidata Solutions in the 2nd quarter worth about $235,000. Zeke Capital Advisors LLC bought a new stake in Medidata Solutions in the 2nd quarter worth about $239,000. First Republic Investment Management Inc. bought a new stake in Medidata Solutions in the 2nd quarter worth about $242,000. Zions Bancorporation bought a new stake in Medidata Solutions in the 2nd quarter worth about $274,000. Finally, Asset Management One Co. Ltd. grew its position in Medidata Solutions by 102.7% in the 1st quarter. Asset Management One Co. Ltd. now owns 3,948 shares of the company’s stock worth $248,000 after purchasing an additional 2,000 shares in the last quarter.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Read More: What Factors Can Affect Return on Equity?

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.